title: A clinical comparison of guided bone regeneration with platelet-derived growth factor-enhanced bone ceramic versus autogenous bone block grafting.
abstract: OBJECTIVE
  The objective of this study was to evaluate the efficacy of guided bone regeneration (GBR) employing recombinant human platelet-derived growth factor-BB (rhPDGF-BB) incorporated into a beta-tricalcium phosphate (β-TCP)/hydroxyapatite (HA) carrier as a graft material and to compare it to autogenous bone block grafting.
  
  
  METHODS
  Adult patients with a site that required bone grafting to increase the thickness of the alveolar bone ridge were treated. After mucoperiosteal flap elevation, experimental bone defects were treated by GBR with rhPDGF incorporated into β-TCP/HA, and control defects were treated with autogenous bone. Primary tension-free wound closure was obtained for all treated sites.
  
  
  RESULTS
  Thirty patients were treated. No significant differences were observed between the groups for any of the parameters evaluated, including the amount of bone regeneration and a need for additional grafting.
  
  
  CONCLUSIONS
  A composite bone ceramic graft that incorporated rhPDGF appears to be a suitable substitute for autogenous bone block grafting when employed in conjunction with GBR in humans.
authors.forename: Ronaldo B
authors.initials: RB
authors.lastname: Santana
authors.forename: Carolina Mm
authors.initials: CM
authors.lastname: Santana
mesh_terms: D000328:Adult; D000368:Aged; D000539:Alveolar Process; D000077214:Becaplermin; D001861:Bone Regeneration; D016025:Bone Transplantation / Q000379:methods*; D002130:Calcium Phosphates / Q000737:chemistry*; D002516:Ceramics / Q000737:chemistry*; D005260:Female; D006801:Humans; D006882:Hydroxyapatites; D008297:Male; D008875:Middle Aged; D016348:Osseointegration; D059035:Perioperative Period; D010982:Platelet-Derived Growth Factor / Q000737:chemistry; D011184:Postoperative Period; D011336:Probability; D011446:Prospective Studies; D020574:Proto-Oncogene Proteins c-sis / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000737:chemistry*
chemical_list: D002130:Calcium Phosphates; D006882:Hydroxyapatites; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; C485817:beta-tricalcium phosphate; C074950:hydroxyapatite-beta tricalcium phosphate; D000077214:Becaplermin